Results 1 to 10 of about 268,104 (311)
The efficacy and safety of intraocular anti-VEGF injections versus anti-VEGF combined with steroids or steroid monotherapy for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis of randomized controlled trials [PDF]
Frontiers in MedicineObjectiveThe study performed a systematic review and meta-analysis of randomized controlled trials (RCTs) assessing the efficacy and safety of intraocular injections of anti-vascular endothelial growth factor (VEGF) monotherapy versus steroid monotherapy
Han Cai +3 more
doaj +2 more sources
Anti-VEGF neutralizing antibody delays osteomucosal healing by reducing collagen formation in mice [PDF]
Scientific ReportsMedication-related osteonecrosis of the jaw (MRONJ) is a detrimental side effect in patients undergoing treatment with antiresorptive agents. The anti-angiogenic agent, bevacizumab (anti-VEGF antibody (Ab)), has also been reported to be associated with ...
Eun-Bin Bae +11 more
doaj +2 more sources
Anti-VEGF drugs: evidence for effectiveness
Community Eye Health Journal, 2014 Anti-vascular endothelial growth factors (anti-VEGF) are targeted biological drugs (e.g. monoclonal antibodies) that prevent the growth of new vessels by inhibiting VEGF.
Jennifer Evans , Gianni Virgili
doaj +2 more sources
Journal of Ophthalmology, 2021 Background/Objectives. Currently, in England, antivascular endothelial growth factor (anti-VEGF) is the first-line treatment for diabetic macular oedema (DMO) where central macular thickness (CMT) is ≥400 microns.
Di Zou, Imran Jawaid, Winfried M. Amoaku
doaj +1 more source
BMJ Open, 2023 Objectives To evaluate the efficacy and safety of anti-vascular endothelial growth factor (anti-VEGF) therapy for myopia choroidal neovascularisation (CNV), and to compare the efficacy of two different anti-VEGF retreatment criteria.Data sources PubMed ...
Chao Zhang +5 more
doaj +1 more source
Mechanistic insights into the heterogeneous response to anti‐VEGF treatment in tumors
Computational and Systems Oncology, 2021 Vascular endothelial growth factor (VEGF) is a strong promoter of angiogenesis in tumors, and anti‐VEGF treatment, such as a humanized antibody to VEGF, is clinically used as a monotherapy or in combination with chemotherapy to treat cancer patients ...
Ding Li, Stacey D. Finley
doaj +1 more source
Journal of Ophthalmology, 2021 Purpose. To evaluate whether treatment with intravitreal corticosteroid and anti-vascular endothelial growth factor (VEGF) injections alternately can improve treatment outcomes of macular edema (ME) caused by retinal vein occlusion (RVO). Methods.
Young Hwan Bae +5 more
doaj +1 more source
VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy
Annals of Medicine, 2022 Diabetic retinopathy (DR) is the most common microangiopathic complication of diabetes mellitus, representing a major cause of visual impairment in developed countries.
Alessandro Arrigo +2 more
doaj +1 more source
Scientific Reports, 2021 We evaluated changes in the complement system resulting from anti-vascular endothelial growth factor (VEGF) in eyes with age-related choroidal neovascularization (CNV) including neovascular age-related macular degeneration, pachychoroid neovasculopathy ...
Keiichiro Tanaka +13 more
doaj +1 more source
Anti VEGF for post op CME- Boon or Bane!
TNOA Journal of Ophthalmic Science and Research, 2022 Cataract surgery has advanced in techniques and instrumentation over the years, but complications such as cystoid macular edema (CME) do occur even after uneventful surgery.
Roshni Mohan, M Arthi, S Balamurugan
doaj +1 more source